Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,285
  • Shares Outstanding, K 52,300
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,867 K
  • 36-Month Beta 2.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.46

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.54 +18.90%
on 02/09/18
3.68 -17.93%
on 01/29/18
-0.17 (-5.33%)
since 01/19/18
3-Month
2.36 +27.97%
on 11/22/17
4.09 -26.16%
on 12/27/17
+0.66 (+27.97%)
since 11/21/17
52-Week
1.10 +174.55%
on 06/19/17
4.09 -26.16%
on 12/27/17
+1.61 (+114.18%)
since 02/21/17

Most Recent Stories

More News
Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

Data reinforce the potential clinical utility of combination therapy -

SRRA : 3.02 (+2.37%)
Stock Review for Biotech's Investors -- Sage Therapeutics, Sarepta Therapeutics, Sierra Oncology, and Sorrento Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on SAGE, SRPT, SRRA, and SRNE which can be accessed for free by signing up to www.wallstequities.com/registration....

SRNE : 9.05 (+2.84%)
SRPT : 63.22 (+0.56%)
SRRA : 3.02 (+2.37%)
SAGE : 163.86 (+0.42%)
Sierra Oncology to host Program Update in New York on February 27th

Sierra also to present at the BIO CEO & Investor Conference in New York on February 12th -

SRRA : 3.02 (+2.37%)
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit

"Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" scheduled for 2:15 pm ET on February 1, 2018 in Boston -

SRRA : 3.02 (+2.37%)
Sierra Oncology (SRRA) in Focus: Stock Moves 10.5% Higher

Sierra Oncology (SRRA) was a big mover last session, as the company saw its shares rise nearly 11% on the day.

SRRA : 3.02 (+2.37%)
CSRMY : 16.6500 (+4.06%)
Sierra Oncology Reports Third Quarter Results

- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK -- On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund...

SRRA : 3.02 (+2.37%)
Sierra Oncology Reports Third Quarter Results

Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK - - On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund...

SRRA : 3.02 (+2.37%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 3.02 (+2.37%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

"Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 3.02 (+2.37%)
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

- SRA737 demonstrates synergy with replication stress-inducing agents -- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -- SRA737 potentiated by novel sub-therapeutic gemcitabine...

SRRA : 3.02 (+2.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central...

See More

Key Turning Points

2nd Resistance Point 3.35
1st Resistance Point 3.19
Last Price 3.02
1st Support Level 2.91
2nd Support Level 2.79

See More

52-Week High 4.09
Last Price 3.02
Fibonacci 61.8% 2.95
Fibonacci 50% 2.60
Fibonacci 38.2% 2.24
52-Week Low 1.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.